Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Adult Acute Lymphoblastic Leukemia: early-phase trial registry
1 of 2 indexed Refractory Adult Acute Lymphoblastic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Refractory Adult Acute Lymphoblastic Leukemia: 2 US clinical trials tracked, 1 recruiting.
Refractory Adult Acute Lymphoblastic Leukemia is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 1 of these trials.
Enrollment posture brief
Registry condition refractory-adult-acute-lymphoblastic-leukemia
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Refractory Adult Acute Lymphoblastic Leukemia lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Adult Acute Lymphoblastic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Adult Acute Lymphoblastic Leukemia is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT03326921
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT02484430
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Adult Acute Lymphoblastic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Adult Acute Lymphoblastic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Adult Acute Lymphoblastic Leukemia page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Refractory Adult Acute Lymphoblastic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fred Hutchinson Cancer Center sponsors the most Refractory Adult Acute Lymphoblastic Leukemia trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Adult Acute Lymphoblastic Leukemia condition card totals 2 registered trials; most-linked intervention Pharmacological Study; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.